Clinical trial
A Phase II Multi-Institutional Trial of Focal Radiotherapy With Concomitant Carboplatin as a Radiosensitizer and the Prospective Analysis of Survivin, an Inhibitor of Apoptosis, as a Biomarker in Children With Newly Diagnosed Non-Metastatic Ependymoma and Minimal Residual Disease Post-Operatively
NCT01088035 is registered in ClinicalTrials.gov with Ann & Robert H Lurie Children's Hospital of Chicago as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Multi-Institutional Trial of Focal Radiotherapy With Concomitant Carboplatin as a Radiosensitizer and the Prospective Analysis of Survivin, an Inhibitor of Apoptosis, as a Biomarker in Children With Newly Diagnosed Non-Metastatic Ependymoma and Minimal Residual Disease Post-Operatively
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- April 30, 2010
- Completion date
- April 30, 2015
- Enrollment
- 75 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.